Revvity (RVTY) has been performing well with clinical trial successes causing a 1.98% increase in share value. The leading biotech firm is holding its earnings call on July 28, 2025, and the first-quarter earnings are expected to decline. UBS has upgraded Revvity, indicating market confidence in the company. Despite facing headwinds, the shares of Revvity are deemed a good buy. Various analyst firms including Barclays and Evercore ISI have maintained strong ratings and positive price targets for the company.
Financially, the company reported better-than-expected Q4 earnings, and also announced strong organic growth and strategic achievements in calls, although some analysts warn of potential underperformance compared to the Dow.
Innovatively, Revvity has introduced new Mimix standards for improved in-vitro diagnostic testing (IVD) and unveiled a fully automated instrument for specialty testing. Amidst tariff warnings and facing price target cuts due to funding concerns, the company continues to show potential with upcoming earnings calls and key product launches. Regulatory approvals received by Revvity such as an FDA nod for an automated tuberculosis test further reflect their strength in the diagnostics field. Moving forward, the company seems geared up to present at various healthcare conferences.
Revvity RVTY News Analytics from Tue, 16 May 2023 16:23:00 GMT to Tue, 08 Jul 2025 22:49:35 GMT -
Rating 4
- Innovation 7
- Information 6
- Rumor -2
